Increased beta-lactamase activity in Branhamella catarrhalis after exposure to amoxicillin and clavulanic acid. 1994

B Bedenić, and Z Zagar
School of Public Health A. Stampar, Department of Medical Microbiology, Zagreb, Croatia.

Branhamella catarrhalis, previously regarded as a harmless member of the normal nasopharyngeal flora, has periodically been implicated as the major pathogen in representative cases of a variety of infections such as sinusitis, pneumonia, septicemia and meningitis. In addition, beta-lactamase production of these microorganisms, first described in 1977, has been reported with increasing frequency, up to 80%. The first-choice drug for the therapy of the infections caused by beta-lactamase producing strains of B. catarrhalis is amoxicillin combined with clavulanic acid. The aim of our work was to determine the influence of amoxicillin and clavulanic acid on the biosynthesis of beta-lactamase of B. catarrhalis. Our results point out that the combination of amoxicillin and clavulanic acid produces only a slight increase in enzyme activity in 5003 and 462 strains. Clavulanic acid alone caused no increase in enzyme production. Ravasio strain showed no increase in enzyme formation after exposure to antibiotics.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D001936 Moraxella catarrhalis Gram-negative aerobic cocci of low virulence that colonize the nasopharynx and occasionally cause MENINGITIS; BACTEREMIA; EMPYEMA; PERICARDITIS; and PNEUMONIA. Branhamella catarrhalis,Mikrokkokus catarrhalis,Moraxella (Branhamella) catarrhalis
D002969 Clavulanic Acids Acids, salts, and derivatives of clavulanic acid (C8H9O5N). They consist of those beta-lactam compounds that differ from penicillin in having the sulfur of the thiazolidine ring replaced by an oxygen. They have limited antibacterial action, but block bacterial beta-lactamase irreversibly, so that similar antibiotics are not broken down by the bacterial enzymes and therefore can exert their antibacterial effects. Acids, Clavulanic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D000658 Amoxicillin A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration. Hydroxyampicillin,Actimoxi,Amoxicillin Anhydrous,Amoxicillin Monopotassium Salt,Amoxicillin Monosodium Salt,Amoxicillin Sodium,Amoxicillin Trihydrate,Amoxicillin, (R*)-Isomer,Amoxicilline,Amoxil,Amoxycillin,BRL-2333,Clamoxyl,Clamoxyl G.A.,Clamoxyl Parenteral,Penamox,Polymox,Trimox,Wymox,BRL 2333,BRL2333
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001618 beta-Lactamases Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins. beta-Lactamase,beta Lactamase,beta Lactamases
D019818 Clavulanic Acid A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase. Clavulanate,BRL-14151,Clavulanate Potassium,Clavulanic Acid, Monopotassium Salt,Clavulanic Acid, Monosodium Salt,MM-14151,Potassium Clavulanate,Sodium Clavulanate,BRL 14151,BRL14151,Clavulanate, Potassium,Clavulanate, Sodium,MM 14151,MM14151,Potassium, Clavulanate
D019980 Amoxicillin-Potassium Clavulanate Combination A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate. Amoxicillin-Clavulanic Acid,Potassium Clavulanate-Amoxicillin Combination,Amox-clav,Amoxi-Clavulanate,Amoxycillin-Clavulanic Acid,Augmentin,BRL-25000,Clavulanate Potentiated Amoxycillin,Clavulin,Co-amoxiclav,Coamoxiclav,Spektramox,Synulox,Amox clav,Amoxi Clavulanate,Amoxicillin Clavulanic Acid,Amoxicillin Potassium Clavulanate Combination,Amoxycillin Clavulanic Acid,Amoxycillin, Clavulanate Potentiated,BRL 25000,BRL25000,Co amoxiclav,Potassium Clavulanate Amoxicillin Combination

Related Publications

B Bedenić, and Z Zagar
June 1988, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
B Bedenić, and Z Zagar
December 1986, European journal of clinical microbiology,
B Bedenić, and Z Zagar
March 1982, Antimicrobial agents and chemotherapy,
B Bedenić, and Z Zagar
October 1978, Annales de microbiologie,
B Bedenić, and Z Zagar
January 1986, Drugs,
B Bedenić, and Z Zagar
September 1984, Lancet (London, England),
B Bedenić, and Z Zagar
February 1981, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!